Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY4060874 · 1 trial · 1 indication
Number of participants with one or more TEAEs and SAEs.
| Arm | Type | Description |
|---|---|---|
| LY4060874 (Part A Subcutaneous) | EXPERIMENTAL | Single ascending dose of LY4060874 administered subcutaneously (SC). |
| LY4060874 (Part A Intravenous) | EXPERIMENTAL | Single ascending dose of LY4060874 administered intravenously (IV). |
| LY4060874 (Part B) | EXPERIMENTAL | Multiple ascending doses of LY4060874 administered SC. |
| LY4060874 (Part B Chinese) | EXPERIMENTAL | Multiple ascending doses of LY4060874 administered SC in Chinese participants. |
| LY4060874 (Part C Japanese) | EXPERIMENTAL | Multiple ascending doses of LY4060874 administered SC in Japanese participants. |
| Placebo (SC) | PLACEBO_COMPARATOR | Placebo administered SC in Part A, B, and C. |
| Placebo (IV) | PLACEBO_COMPARATOR | Placebo administered IV in Part A. |
| Name | Type | Description |
|---|---|---|
| LY4060874 | DRUG | Administered SC |
| Placebo | DRUG | Administered SC |
Inclusion Criteria: * Are overtly healthy as determined by medical evaluation, including medical history and physical examination. * Have a body mass index in the range of 20 to 29.9 kilogram per meter squared (kg/m²), inclusive, at screening. * To qualify as Chinese for this study, all 4 of the pa...
LY4060874 is an investigational small molecule developed by Eli Lilly and Company. It has been studied in a Phase 1 clinical trial in healthy adult participants. The specific disease or condition it is intended to treat has not been disclosed, so its therapeutic use is not publicly defined at this stage.
LY4060874 is being developed by Eli Lilly and Company, which trades on the New York Stock Exchange under the ticker LLY. Lilly is the sponsor of the clinical program studying this small molecule compound.
LY4060874 is in Phase 1 clinical development. Its only recorded trial, NCT06709820, was a Phase 1 study that has been completed. The drug is investigational and has not been approved by the FDA for any indication.
LY4060874 has been evaluated in one clinical trial, NCT06709820, titled A Study of LY4060874 in Healthy Participants. The Phase 1 trial was completed and enrolled 121 healthy volunteers across the United States and Singapore. It was randomized, double-blind, and placebo-controlled, with participants aged 18 years and older.
No. LY4060874 is an investigational drug in Phase 1 clinical development and is not FDA approved for any indication. Its single completed trial studied the drug in healthy participants rather than in patients with a specific disease.
The Phase 1 trial NCT06709820 studied LY4060874 in 121 healthy participants aged 18 years and older in the United States and Singapore. It used a randomized, double-blind, placebo-controlled design. The trial has been completed, and no further active trials of LY4060874 are currently listed.